ERBB2 and breast carcinoma: Assessment of the Efficacy and Pulmonary Toxicity of Trastuzumab Deruxtecan in HER2-Positive and HER2-Low Metastatic Breast Cancer in a Tertiary Center in the United Arab Emirates